Use of Insulin Glargine to Treat Diabetic Ketoacidosis
Diabetic Ketoacidosis
About this trial
This is an interventional treatment trial for Diabetic Ketoacidosis focused on measuring Pediatrics, Diabetes, Emergency Care, Endocrinology, Critical Care
Eligibility Criteria
Inclusion Criteria: Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with: Established history of insulin dependent diabetes AND: Chief c/o hyperglycemia or vomiting Venous pH < 7.24 Serum Bicarbonate < 18 Blood glucose > 150 Urinary Ketones Exclusion Criteria: Age < 6y.o. New onset diabetes Received IV insulin bolus prior to arrival to VCH Emergency Room (ER) Venous pH > 7.24 Serum Bicarbonate > 18 Pregnancy Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit
Sites / Locations
- Vanderbilt University Monroe Carell Children's Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Glargine
Placebo
0.3u/kg of glargine, subcutaneously, once
0.3u/kg of saline, subcutaneously, once